Skip to content
DraconiticResearch
Search Sources API
194,161 studies31 sourcesUpdated 51 min ago
Peer-reviewedCC BYFrontiers in oncology

AGE-related efficacy and safety of darolutamide triplet therapy in metastatic hormone-sensitive prostate cancer: are we ready for routine clinical practice?

  • Fernando Munoz1
  • Francesco Fiorica2
  1. 1Department Radiation Oncology, Aosta, Italy.
  2. 2Department of Medical Oncology, Aulss 9 Scaligera, Verona, Italy.
Read full textPDFDOICite

Related

  1. Clinical and genomic determinants of extraordinary response and resistance to androgen receptor pathway inhibitors in men with metastatic androgen pathway modulator sensitive (APMS) prostate cancer
    Jane McKenzie, Lauren Howard, Joseph J. Park +13
    Prostate Cancer and Prostatic DiseasesPeer-reviewedCC BY 4.0Full textGeneral medicinePMC
  2. Exceptional long-term responses in metastatic androgen pathway-modulation sensitive prostate cancer
    Varun Nandakumar, Georges Gebrael, Neeraj Agarwal
    The OncologistPeer-reviewedCC BY-NC 4.0Full textGeneral medicinePMC
  3. The Role of Dominant Lesion Site and SUVmax in the Depth of PSA Response in Metastatic Hormone-Sensitive Prostate Cancer
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Cost-effectiveness of adding enzalutamide vs standard non-steroidal antiandrogen drugs for patients with metastatic hormone-sensitive prostate cancer undergoing standard first-line therapy: a within-trial, secondary end-point analysis of the ENZAMET phase 3, international randomized trial (ANZUP 1304)
    Chi Kin Law, Martin R. Stockler, Andrew J. Martin +3
    EClinicalMedicinePeer-reviewedCC BYFull textGeneral medicineEurope PMCCrossref
  5. [¹⁷⁷Lu]Lu-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer: Evidence from PSMAddition and Considerations for Treatment Sequencing.
    Carlo Buonerba, Giuseppe Di Lorenzo
    Current oncology (Toronto, Ont.)Peer-reviewedCC BYFull textOncologyEurope PMCDOAJ

Cite

BibTeXRIS
BibTeX
@article{munoz2026agerelated,
  title = {{AGE-related efficacy and safety of darolutamide triplet therapy in metastatic hormone-sensitive prostate cancer: are we ready for routine clinical practice?}},
  author = {Fernando Munoz and Francesco Fiorica},
  journal = {Frontiers in oncology},
  year = {2026},
  month = oct,
  doi = {10.3389/fonc.2026.1971526},
  url = {https://europepmc.org/article/MED/42898144},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - AGE-related efficacy and safety of darolutamide triplet therapy in metastatic hormone-sensitive prostate cancer: are we ready for routine clinical practice?
AU  - Fernando Munoz
AU  - Francesco Fiorica
PY  - 2026
DA  - 2026/10/05
JO  - Frontiers in oncology
DO  - 10.3389/fonc.2026.1971526
UR  - https://europepmc.org/article/MED/42898144
SN  - 2234-943X
ER  -